Cover Image
市場調查報告書

PharmaPoint:B型肝炎病毒(HBV)預防疫苗--美國的醫藥品的預測與市場分析

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298832
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:B型肝炎病毒(HBV)預防疫苗--美國的醫藥品的預測與市場分析 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 136 Pages
簡介

全球有20億人感染B型肝炎病毒(HBV),每年都有60萬人因B型肝炎相關肝疾病而死亡。自混合HBsAg疫苗出現以來,這二十年來大幅減輕了這個疾病帶來的負擔,但仍留有成人的疫苗攝取及有效性(尤其是特殊病患上)的問題。一般認為今後高風險成人患者的高血清轉換率的達成、各國政策上的對策、尤其是美國功兒患者的混合疫苗的普及率,都會推動市場的成長。

本報告提供美國的B型肝炎病毒(HBV)預防疫苗相關的最新研究·開發情形及相關市場未來展望分析,彙整疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),現在銷售中及臨床實驗中主要的疫苗簡介,美國市場現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因與病情
    • 病因
    • 病理
  • 症狀
  • 預測

第4章 疫苗的接種宣導與攝取率

  • 概要
  • 美國
    • 預防接種的建議與政策
    • 攝取率
    • 臨床診療

第5章 競爭環境

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:單價疫苗
    • Engerix-B
    • Recombivax HB
  • 產品簡介:混合疫苗
    • Pediarix
    • Hexyon
    • Comvax
    • Twinrix

第6章 市場機會及未滿足需求

  • 概要
  • 疫苗免疫抗原性的增加
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 疫苗接種率的上升
  • 患者意識的提升
  • 醫生教育的改善
  • 成本效益高的疫苗

第7章 開發平台分析

  • 概要
  • 臨床實驗後期階段產品中的有潛力疫苗
    • Heplisav
  • 臨床實驗初期階段產品中的有潛力疫苗

第8章 市場預測

  • 美國
    • 市場預測
    • 主要趨勢
    • 市場促進·阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC214CFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

The drivers and barriers that GlobalData projects to most heavily influence growth of the US HBV vaccine market during the forecast period. In the pediatric segment of the marketplace, where annual coverage rates consistently reach 90%, this growth will be driven primarily by the increased use of combination vaccines for routine immunization, as these vaccines are looked upon favorably by both parents and physicians due to their ability to protect infants against multiple diseases with a single series of shots.

Scope

  • Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Hepatitis B disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the US

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview
  • 4.2. US
    • 4.2.1. Immunization Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Monovalent Vaccines
    • 5.3.1. Engerix-B
    • 5.3.2. Recombivax HB
  • 5.4. Product Profiles - Combination Vaccines
    • 5.4.1. Pediarix
    • 5.4.2. Hexyon
    • 5.4.3. Comvax
    • 5.4.4. Twinrix

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Late-Stage Clinical Development
    • 7.2.1. Heplisav
  • 7.3. Promising Vaccines in Early-Stage Clinical Development

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Patient Populations Targeted for Vaccination
    • 9.4.2. Vaccination Coverage Rates
    • 9.4.3. Vaccinated Patients
    • 9.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 9.4.5. Vaccines Included
    • 9.4.6. Key Launch Dates
    • 9.4.7. General Pricing Assumptions
    • 9.4.8. Individual Vaccine Assumptions
    • 9.4.9. Pricing of Pipeline Vaccines
  • 9.5. Physicians and Specialists Included in this Study
    • 9.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 9.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Engerix-B
  • Table 9: Immunogenicity Profile - Engerix-B
  • Table 10: Safety Profile - Engerix-B
  • Table 11: Engerix-B SWOT Analysis, 2014
  • Table 12: Product Profile - Recombivax HB
  • Table 13: Immunogenicity Profile - Recombivax HB
  • Table 14: Safety Profile - Recombivax HB
  • Table 15: Recombivax HB SWOT Analysis, 2014
  • Table 16: Product Profile - Pediarix
  • Table 17: Immunogenicity Profile - Pediarix
  • Table 18: Safety Profile - Pediarix
  • Table 19: Pediarix SWOT Analysis, 2014
  • Table 20: Product Profile - Hexyon
  • Table 21: Immunogenicity Profile - Hexyon
  • Table 22: Safety Profile - Hexyon
  • Table 23: Hexyon SWOT Analysis, 2014
  • Table 24: Product Profile - Comvax
  • Table 25: Immunogenicity Profile - Comvax
  • Table 26: Safety Profile - Comvax
  • Table 27: Comvax SWOT Analysis, 2014
  • Table 28: Product Profile - Twinrix
  • Table 29: Immunogenicity Profile - Twinrix
  • Table 30: Safety Profile - Twinrix
  • Table 31: Twinrix SWOT Analysis, 2014
  • Table 32: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 33: HBV Vaccines - Phase Pipeline, 2014
  • Table 34: Comparison of Vaccines in Development for HBV, 2014
  • Table 35: Product Profile - Heplisav
  • Table 36: Immunogenicity Profile - Heplisav
  • Table 37: Safety Profile - Heplisav
  • Table 38: Heplisav SWOT Analysis, 2014
  • Table 39: Sales Forecasts ($m) for HBV Vaccines in the United States, 2012-2022
  • Table 40: Key Events Impacting Sales for HBV Vaccines in the United States, 2014
  • Table 41: United States HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 42: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, US
  • Table 43: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, US
  • Table 44: Key Launch Dates
  • Table 45: High-Prescribing Physicians (non-KOLs) Surveyed, US

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
  • Figure 2: Routine HBV Vaccination Coverage (%) in the United States
  • Figure 3: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United States, 2014
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents and Marketed Products in HBV Vaccines, 2012-2022
  • Figure 5: Sales for HBV Vaccines in the US, 2012-2022
Back to Top